Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
- Revenue in AUD (TTM)256.62k
- Net income in AUD-40.50m
- Incorporated1987
- Employees19.00
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY NSW 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Argenica Therapeutics Ltd | 92.21k | -4.67m | 106.38m | -- | -- | 12.93 | -- | 1,153.70 | -0.0511 | -0.0511 | 0.001 | 0.0665 | 0.0109 | -- | 0.6384 | -- | -55.31 | -- | -69.00 | -- | -- | -- | -5,067.62 | -- | -- | -6,663.20 | 0.00 | -- | 2,340.00 | -- | -17.71 | -- | -- | -- |
Paradigm Biopharmaceuticals Ltd | 8.67m | -69.00m | 108.44m | -- | -- | 3.22 | -- | 12.51 | -0.2296 | -0.2296 | 0.0288 | 0.0962 | 0.1298 | -- | 2.25 | -- | -103.34 | -40.96 | -127.58 | -44.13 | 99.87 | -- | -796.30 | -466.85 | -- | -348.76 | 0.0085 | -- | 7.58 | 25.42 | -32.26 | -- | -- | -- |
Proteomics International LaboratoriesLtd | 1.44m | -5.90m | 123.14m | -- | -- | 21.49 | -- | 85.22 | -0.0518 | -0.0518 | 0.0129 | 0.0437 | 0.1817 | -- | 11.13 | -- | -75.75 | -57.79 | -87.11 | -67.57 | -- | -- | -416.78 | -229.69 | -- | -283.47 | 0.0088 | -- | -14.64 | 4.12 | -24.20 | -- | 89.02 | -- |
Arovella Therapeutics Ltd | 139.02k | -10.23m | 183.97m | 14.00 | -- | 50.80 | -- | 1,323.36 | -0.0127 | -0.0127 | 0.0002 | 0.0034 | 0.0249 | -- | 15.15 | -- | -182.82 | -77.12 | -276.07 | -93.26 | 83.56 | 63.41 | -7,357.19 | -1,471.57 | -- | -- | 0.00 | -- | 45.47 | 0.3491 | -18.11 | -- | -68.72 | -- |
Cogstate Ltd | 62.14m | 8.25m | 200.50m | 61.00 | 26.58 | 3.54 | 16.21 | 3.23 | 0.0442 | 0.0442 | 0.3367 | 0.3314 | 0.7757 | -- | 5.58 | -- | 10.30 | 6.01 | 13.84 | 9.22 | 54.69 | 51.50 | 13.28 | 7.26 | -- | -- | 0.0135 | 0.00 | -8.62 | 7.25 | -52.56 | -- | -5.06 | -- |
Actinogen Medical Ltd | 337.51k | -14.87m | 242.51m | -- | -- | 17.58 | -- | 718.52 | -0.0073 | -0.0073 | 0.0002 | 0.0051 | 0.0211 | -- | 0.7341 | -- | -92.99 | -45.55 | -105.88 | -48.24 | -- | -- | -4,405.86 | -5,369.76 | -- | -294.93 | 0.0037 | -- | 792.74 | 31.88 | -13.21 | -- | 166.95 | -- |
Dimerix Ltd | 181.28k | -10.87m | 288.86m | 0.00 | -- | 130.32 | -- | 1,593.46 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
Race Oncology Ltd | 885.59k | -11.17m | 316.85m | -- | -- | 14.88 | -- | 357.78 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
Imugene Ltd | 0.00 | -89.24m | 411.56m | 0.00 | -- | 2.06 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
Immutep Ltd | 256.62k | -40.50m | 421.26m | 19.00 | -- | 3.01 | -- | 1,641.56 | -0.039 | -0.039 | 0.0002 | 0.0964 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
Opthea Ltd | 175.25k | -241.86m | 470.97m | 5.00 | -- | -- | -- | 2,687.44 | -0.427 | -0.427 | 0.0003 | -0.0976 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
PYC Therapeutics Ltd | 21.54m | -21.65m | 536.60m | 23.00 | -- | 14.36 | -- | 24.91 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
Holder | Shares | % Held |
---|---|---|
Regal Funds Management Pty Ltd.as of 12 Jun 2024 | 121.23m | 9.60% |
Perennial Value Management Ltd.as of 13 Jun 2024 | 71.74m | 5.68% |
MLC Investments Ltd.as of 12 Jun 2024 | 67.01m | 5.31% |
Milford Asset Management Ltd.as of 13 Feb 2024 | 62.12m | 4.92% |
FIL Investment Management (Hong Kong) Ltd.as of 31 May 2024 | 46.19m | 3.66% |
IOOF Investment Services Ltd.as of 12 Jun 2024 | 44.42m | 3.52% |
Antares Capital Partners Ltd.as of 12 Jun 2024 | 15.09m | 1.20% |
HB Biotechnology Ltd.as of 22 Aug 2023 | 6.54m | 0.52% |
DFA Australia Ltd.as of 31 May 2024 | 6.03m | 0.48% |
Dimensional Fund Advisors LPas of 04 Jul 2024 | 5.21m | 0.41% |